Advertisement

Topics

Novo Nordisk Diabetes Drug Beats Lilly’s Trulicity in Head-to-Head Test

14:30 EDT 17 Aug 2017 | Xconomy

A Novo Nordisk drug candidate for type 2 diabetes beat Eli Lilly’s dulaglutide (Trulicity) in reducing blood sugar and body weight in patients studied in a late-stage clinical trial, the Denmark-based company says. The results could bring strong competition to one of Indianapolis-based Lilly’s top-selling products if Novo Nordisk’s experimental drug is approved by the […]

Original Article: Novo Nordisk Diabetes Drug Beats Lilly’s Trulicity in Head-to-Head Test

NEXT ARTICLE

More From BioPortfolio on "Novo Nordisk Diabetes Drug Beats Lilly’s Trulicity in Head-to-Head Test"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...